Pharmaceutical

FDA expands approval of Dupixent for eosinophilic esophagitis in children

Regeneron and Sanofi’s blockbuster anti-inflammatory drug generated global sales of $8.68bn in 2022.

Jan 27, 2024 - 18:00
FDA expands approval of Dupixent for eosinophilic esophagitis in children
Regeneron and Sanofi’s blockbuster anti-inflammatory drug generated global sales of $8.68bn in 2022.
Read the original article

Tags:

Previous Article

Atossa Therapeutics progresses Phase II preventative breast cancer therapy

Next Article

Travere signs $120m licensing deal with Renalys for sparsentan in Asia

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA pushes back on approving mirikizumab due to manufacturing issues

FDA pushes back on approving mirikizumab due to manufac...

Apr 22, 2023

(Edetate disodium + ethyl alcohol + minocycline hydroch...

Feb 8, 2024

Inflationary pressure causes drop-off in contract manufacturing M&A

Inflationary pressure causes drop-off in contract manuf...

Jul 29, 2023